| Name | NGI-1 |
|---|---|
| Synonyms |
MFCD06358908
5-(Dimethylsulfamoyl)-N-(5-methyl-1,3-thiazol-2-yl)-2-(1-pyrrolidinyl)benzamide Benzamide, 5-[(dimethylamino)sulfonyl]-N-(5-methyl-2-thiazolyl)-2-(1-pyrrolidinyl)- |
| Description | NGI-1 is a cell permeable inhibitor. |
|---|---|
| Related Catalog | |
| In Vitro | NGI-1 blocks EGFR N-linked glycosylation in lung adenocarcinoma cells as assessed. In controls EGFR is biotinylated, consistent with its plasma membrane expression, but in NGI-1 treated cells the EGFR is predominantly found in the non-biotinylated intracellular fraction suggesting a change in cellular localization[1]. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Molecular Formula | C17H22N4O3S2 |
| Molecular Weight | 394.512 |
| Exact Mass | 394.113342 |
| LogP | 2.75 |
| Index of Refraction | 1.634 |
| Storage condition | -20℃ |